v3.25.3
Net financial results
 9 Months Ended
Sep. 30, 2025
Notes and other explanatory information [abstract]  
Disclosure of financial results
26 NET FINANCIAL RESULT
09/30/202509/30/2024
Financial expenses
Interest on loans, financing and debentures (1)

(4,194,406)(3,059,902)
Premium expenses on early settlements(89,026)
Amortization of transaction costs

(75,916)(57,716)
Interest expenses on lease liabilities (2)

(347,320)(335,223)
Other

(363,271)(397,459)
(5,069,939)(3,850,300)
Financial income

Cash and cash equivalents and marketable securities

1,144,245 1,212,405 
Other139,962 89,638 
1,284,207 1,302,043 
Results from derivative financial instruments

Income

9,008,280 2,401,971 
Expenses(1,576,658)(6,144,397)
7,431,622 (3,742,426)
Monetary and exchange rate variations, net

Exchange rate variations on loans, financing and debentures

10,914,087 (8,012,235)
Leases381,893 (280,673)
Other assets and liabilities (3)
(1,768,911)1,337,630 
9,527,069 (6,955,278)
Net financial result13,172,959 (13,245,961)
(1)Excludes R$205,409 arising from capitalized loan costs, substantially related to property, plant and equipment in progress of the Cerrado Project for the nine-month period ended September 30, 2025 (R$833,401 as at September 30, 2024).
(2)Includes R$200,177 referring to the reclassification to the biological assets item for the composition of the formation cost (R$184,776 as of September 30, 2024).
(3)Includes effects of exchange rate variations of trade accounts receivable, trade accounts payable, cash and cash equivalents, marketable securities and others.